Entering text into the input field will update the search result below

Phathom gets FDA review for vonoprazan to treat heartburn, erosive esophagitis

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • The U.S. Food and Drug Administration (FDA) accepted to review Phathom Pharmaceuticals' (NASDAQ:PHAT) application seeking approval of oral medicine vonoprazan to treat adults with erosive esophagitis (EE).
  • The company's New Drug Application (NDA) for vonoprazan is for healing of all grades

Recommended For You

About PHAT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PHAT--
Phathom Pharmaceuticals, Inc.